<DOC>
	<DOCNO>NCT00003089</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Chemoprotective drug , amifostine , may protect normal cell side effect chemotherapy . Radiation therapy use high-energy x-rays damage tumor cell . PURPOSE : Phase II trial study effectiveness paclitaxel , carboplatin , amifostine , radiation therapy treat patient unresectable locally advance partially resect non-small cell lung cancer .</brief_summary>
	<brief_title>Chemotherapy , Amifostine , Radiation Therapy Treating Patients With Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxic effect antitumor efficacy paclitaxel plus carboplatin patient unresectable , intrathoracic non-small cell lung cancer ( NSCLC ) . II . Integrate concurrent thoracic radiation therapy weekly low dose paclitaxel treatment patient population . III . Investigate primary chemoradiotherapy treatment approach population patient select basis performance status regardless degree weight loss . IV . Determine effect amifostine incidence treatment nonhematologic toxic effect , specifically esophagitis , pneumonitis , radiation dermatitis , patient . OUTLINE : This open label study . Patients receive induction therapy comprise paclitaxel IV 3 hour follow carboplatin IV 1 hour day 1 21 . Patients undergo radiotherapy begin day 42 ( later day 63 ) daily 5 day week 7 week . Patients also receive amifostine IV 15 minute follow paclitaxel IV 3 hour weekly ( day 1 week ) concurrently duration radiotherapy . On 2 day week , patient receive amifostine alone precede thoracic radiotherapy . Patients follow every 3 month 1 year every 6 month disease progression death . PROJECTED ACCRUAL : Approximately 15-35 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically prove nonsmall cell lung cancer Adenocarcinoma Squamous cell carcinoma Large cell carcinoma Undifferentiated carcinoma Stages IIIIIB Medically inoperable stage II IIIA Unresectable stage IIIA IIIB Partial resection stage IIIA IIIB disease histologically proven mediastinal lymph node involvement microscopic measurable disease Ineligible RTOG 9410 RTOG 9304 Men elevate PSA great 10 clinical evidence prostate carcinoma eligible No pleural effusion large enough visible plain chest radiograph , unless prove benign Limited metastatic disease ( liver metastasis ) define : No 3 lung nodule outside primary tumor suspect metastatic OR No 3 site suspect metastatic disease see bone scan skeletal film OR 13 brain metastasis , plan whole brain irradiation , without surgery radiosurgery OR Single adrenal metastasis exceed 3 cm size PATIENT CHARACTERISTICS : Age : Adult Performance status : ECOG 01 OR Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count great 2,000/mm3 Platelet count great 100,000/mm3 Hemoglobin great 8 g/dL Hepatic : Transaminases less 1.5 time normal Bilirubin le 2.0 mg/dL Renal : Creatinine le 1.8 mg/dL Other : No concurrent severe medical problem Calorie intake least 1500 kcal/day No history active malignancy within one year except : Basal cell carcinoma skin Squamous cell carcinoma skin Superficial transitional cell carcinoma urothelium Cervical intraepithelial neoplasia Stage I cancer endometrium Stage I cancer upper aerodigestive tract PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior thoracic radiotherapy Surgery : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2006</verification_date>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>squamous cell lung cancer</keyword>
	<keyword>large cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
	<keyword>adenocarcinoma lung</keyword>
	<keyword>drug/agent toxicity tissue/organ</keyword>
</DOC>